SLC2A1 and cancer: Our results showed that both pharmacological and genetic inhibition of GLUT1 in CSCs could cause decreased stem cell marker expression, induction of differentiation marker expression, and loss of sphere-forming ability without compromising the viability of CSCs, which was confirmed in CSCs from three different types of human cancer.